The Community As the Patient in Malaria-Endemic Areas: Preempting Drug Resistance with Multiple First-Line Therapies

PLoS Medicine

Volumn 13, Issue 3, 2016, Pages

  Boni, Maciej F ^a,b   White, Nicholas J ^b,c   Baird, J Kevin ^a,b  

^a OXFORD UNIVERSITY CLINICAL RESEARCH UNIT   (Viet Nam)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; ARTEFENOMEL; ARTEMISININ; ARTESUNATE PLUS MEFLOQUINE; CIPARGAMIN; DIHYDROARTEMISININ PLUS PIPERAQUINE; FERROQUINE; ARTEMISININ DERIVATIVE; ARTESUNATE; MEFLOQUINE;

ARTICLE; DRUG DISTRIBUTION; DRUG EFFICACY; ENDEMIC DISEASE; HEALTH PROGRAM; HUMAN; MALARIA; MALARIA CONTROL; MEDICAL PROCEDURES; PHARMACY; PLASMODIUM FALCIPARUM; ANTIBIOTIC RESISTANCE; COMBINATION DRUG THERAPY; HEALTH CARE POLICY; MALARIA, FALCIPARUM;

ANTIMALARIALS; ARTEMISININS; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; ENDEMIC DISEASES; HEALTH POLICY; HUMANS; MALARIA; MALARIA, FALCIPARUM; MEFLOQUINE;

EID: 84962074545     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001984     Document Type: Article

References (20)

1. Peters W, The prevention of antimalarial drug resistance. Pharmac Ther. 1990; 47:499–508.
2. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009; 361:455–467. doi: 10.1056/NEJMoa080885919641202
3. ter Kuile FO, Nosten F, Thieren M, Luxemburger C, Edstein MD, Chongsuphajaisiddhi T, et al. High-dose mefloquine in the treatment of multi-drug resistant falciparum malaria. J Infect Dis. 1992; 166:1393–1400. 1431257
4. Nosten F, van Vugt M, Price R, Luxemburger C, Thway KL, Brockman A, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000; 356:297–302. 11071185
5. Carrara VI, Zwang J, Ashley EA, Price RN, Stepniewska K, Barends M, et al. Changes in the treatment responses to artesunate-mefloquine on the northwestern border of Thailand during 13 years of continuous deployment. PLoS ONE. 2009; 4:e4551. doi: 10.1371/journal.pone.000455119234601
6. A study by the tracking resistance to artemisinin collaboration (TRACII). 2015. https://clinicaltrials.gov/ct2/show/NCT02453308?term=NCT02453308&rank=1.
7. Levins R, Evolution in changing environments. Princeton: Princeton University Press; 1968.
8. Curtis CF, Otoo LN, A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans R Soc Trop Med Hyg. 1986; 80:889–892. 3603638
9. Bonhoeffer S, Lipsitch M, Levin BR, Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA. 1997; 94:12106–12111. 9342370
10. Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, et al. Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob Health. 2015; 3:e758–e766. doi: 10.1016/S2214-109X(15)00162-X26545449
11. Boni MF, Smith DL, Laxminarayan R, Benefits of using multiple first-line therapies against malaria. Proc Natl Acad Sci USA. 2008; 105:14216–14221. doi: 10.1073/pnas.080462810518780786
12. Smith DL, Klein EY, McKenzie FE, Laxminarayan R, Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J. 2010; 9:217. doi: 10.1186/1475-2875-9-21720653960
13. Antao T, Hastings I, Policy options for deploying anti-malarial drugs in endemic countries: a population genetics approach. Malar J. 201211:422. doi: 10.1186/1475-2875-11-42223244624
14. Sutherland CJ, Babiker H, Mackinnon MJ, Ranford-Cartwright L, El Sayed BB, Rational deployment of antimalarial drugs in Africa: should first-line combination drugs be reserved for paediatric cases?Parasitology. 2011; 138:1459–1468. doi: 10.1017/S003118201100114421810298
15. Talisuna A, Grewal P, Rwakimari JB, Mukasa S, Jagoe G, Banerji J, Cost is killing patients: subsidising effective antimalarials. Lancet. 2009; 374:1224–1226. doi: 10.1016/S0140-6736(09)61767-019819377
16. Sabot OJ, Mwita A, Cohen JM, Ipuge Y, Gordon M, Bishop D, et al. Piloting the global subsidy: the impact of subsidized artemisinin-based combination therapies distributed through private drug shops in rural Tanzania. PLoS ONE. 2009; 4:e6857. doi: 10.1371/journal.pone.000685719724644
17. WHO Malaria Policy Committee and SecratariatMalaria Policy Advisory Committee to the WHO: conclusions and recommendations of seventh biannual meeting (March 2015). Malar J. 2015; 14:295. doi: 10.1186/s12936-015-0787-z26242747
18. Ursing J, Kofoed P-E, Rodrigues A, Blessborn D, Thoft-Nielsen R, Björkman A, et al. Similar efficacy and tolerability of double-dose chloroquine and artemether-lumefantrine for treatment of Plasmodium falciparum infection in Guinea-Bissau: a randomized trial. J Infect Dis. 2011; 203:109–116. doi: 10.1093/infdis/jiq00121148503
19. Yeka A, Kigozi R, Conrad MD, Lugemwa M, Okui P, Katureebe C, et al. Artesunate/amodiaquine versus artemether/lumefantrine for the treatment of uncomplicated malaria in Uganda: a randomized trial. J Infect Dis. 2015; e-pub ahead of print, doi: 10.1093/infdis/jiv551
20. Laxminarayan R, Economics of Antibiotic Resistance: A Theory of Optimal Use. J Env Econ Manag. 2001; 42:183–206.